World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
130
Citations
82171
World Ranking
2446
National Ranking
1384

Overview

Lajos Pusztai is affiliated with Yale University in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research is primarily situated within oncology, with a particular focus on breast cancer treatment studies, cancer immunotherapy and biomarkers, and cancer genomics and diagnostics.

Their work spans several subfields, including oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and genetics. Key research topics include advanced breast cancer therapies, HER2/EGFR in cancer research, cancer treatment and pharmacology, as well as cancer cells and metastasis.

Pusztai has authored numerous publications in prominent scientific venues. The most frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • npj Breast Cancer

Some recent notable papers provide insight into the spectrum of their research interests:

  • "Pembrolizumab for Early Triple-Negative Breast Cancer," 2020, New England Journal of Medicine
  • "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer," 2020, JAMA Oncology
  • "Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology
  • "Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer," 2023, Journal of Clinical Oncology
  • "Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue," 2022, JAMA Oncology

In terms of collaboration, Pusztai often works with a consistent group of co-authors, including:

  • William E. Barlow
  • Kathy S. Albain
  • Kim Blenman
  • Christina Yau
  • Laura J. Esserman

Their extensive research reflects a strong emphasis on breast cancer-related studies and cancer immunotherapy, supporting ongoing advancements in treatment strategies and diagnostic approaches. The combination of clinical and molecular work underscores the multidisciplinary nature of their scientific contributions.

Best Publications

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

    Leming Shi;Laura H. Reid;Wendell D. Jones;Richard Shippy

  • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

    Garrett M Frampton;Alex Fichtenholtz;Geoff A Otto;Kai Wang

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Gene-expression signatures in breast cancer.

    Christos Sotiriou;Lajos Pusztai

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

    W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

    Rita R Nanda;Laura Q M Lq Chow;Claire Dees;Raanan R Berger

  • The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai

  • An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

    Katherine Stemke-Hale;Ana Maria Gonzalez-Angulo;Ana Lluch;Richard M. Neve

  • The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

    Leming Shi;Gregory Campbell;Wendell D. Jones;Fabien Campagne

  • Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba

  • Cancer heterogeneity: implications for targeted therapeutics

    R Fisher;L Pusztai;C Swanton;C Swanton

  • The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec

  • Gene expression profiling in breast cancer: classification, prognostication, and prediction

    Jorge S Reis-Filho;Lajos Pusztai

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Triple-negative breast cancer—current status and future directions

    O. Gluz;C. Liedtke;N. Gottschalk;L. Pusztai

  • Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

    Francisco J. Esteva;Vicente Valero;Daniel Booser;Laura T. Guerra

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
W. Fraser Symmans
W. Fraser Symmans The University of Texas MD Anderson Cancer Center
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Francisco J. Esteva
Francisco J. Esteva New York University
David L. Rimm
David L. Rimm Yale University
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center
Jeffrey S. Ross
Jeffrey S. Ross Foundation Medicine
Massimo Cristofanilli
Massimo Cristofanilli Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in Medicine but exploring other flexible pathways? The growing field of online health education offers diverse degree options that complement a traditional MD or serve as alternative routes for healthcare careers.

For those passionate about wellness and preventive care, a best online nutrition degree opens doors to roles in community health, food sciences, or dietary planning. Aspiring healthcare leaders may consider pursuing advanced qualifications through top online mha programs that are cahme accredited, which prepare graduates for management positions in hospitals and health systems.

Registered Nurses seeking career advancement can benefit from rn to bsn no clinical hours programs, allowing diploma or associate degree nurses to earn a bachelor’s degree online without additional clinical requirements. For nurses with a master’s degree, there are also accelerated msn to dnp programs, designed to fast-track a transition to top clinical and leadership roles.

Each pathway provides unique opportunities, balancing flexibility, specialization, and advancement within the ever-evolving healthcare landscape.

Best Scientists Citing Lajos Pusztai

Trending Scientists